|Bid||4.3500 x 1400|
|Ask||4.3600 x 900|
|Day's Range||4.3257 - 4.5300|
|52 Week Range||3.6200 - 9.4200|
|Beta (3Y Monthly)||2.13|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Progenics (PGNX) delivered earnings and revenue surprises of 8.33% and 15.39%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The New York-based company said it had a loss of 22 cents per share. The biopharmaceutical company posted revenue of $4.3 million in the period. Progenics shares have increased 24% since the beginning ...
Progenics (PGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In a series of filings concerning the Pennsylvania-based bank over the past week, activists CT Opportunity Management and Driver Management disclosed that they had submitted proposed terms on March 23. The activist investors, filing together on April 4, reported that DNB Financial had declined to accept the term sheet.
First quarter earnings season kicks off today as we get results from the major banks. While profits are projected to be slightly down from the same period a year ago from companies within the S&P 500, the market seems to be taking this in stride for now.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So before you...
Fourth quarter earnings season has been largely over for large cap names for some time now. However, we still are seeing a trickle of Q4 results come in for some smaller biotech and biopharma names. I thought today we would take a look at a couple of companies we have covered on these pages before and do a post-earnings assessment on them.
Progenics (PGNX) delivered earnings and revenue surprises of -112.50% and -70.54%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the New York-based company said it had a loss of 17 cents. The biopharmaceutical company posted revenue of $3.2 million in the period. For the year, the company reported that its ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 13) Abbott Laboratories (NYSE: ABT ) Akari Therapeutics ...
Invitae guided toward sales of $220 million in fiscal 2019 after achieving $147.7 million in revenue in the just-concluded fiscal year. Invitae tends to provide conservative guidance, so I expect fiscal 2019 revenue to end up in the range of $230 million to $250 million. Invitae continues to be a great proxy for the fast-growing genetic testing space.
Today, we look at a slightly riskier part of the sector in promising small caps that should be able to reach profitability with little to no additional funding needs. Revenues should more than double this year to over $140 million as the genetic test market continues to expand rapidly and Invitae garners market share. The company is doing a good job lessening its cash burn every quarter and is on the path to reach profitability late in 2019.
In 2011 Mark Baker was appointed CEO of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll Read More...
Before we spend many hours researching a company, we’d like to analyze what insiders, hedge funds and billionaire investors think of the stock first. We would like to do so because the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of […]
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
Progenics (PGNX) delivered earnings and revenue surprises of 50.00% and 28.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The New York-based company said it had a loss of 30 cents per share. Losses, adjusted for one-time gains and costs, were 9 cents per share. The biopharmaceutical company posted revenue of $5.3 million ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Amid the market mayhem, no biotech or medical device companies made it to 52-week highs. Down In The Dumps (Biotech stocks ...
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX ) shares were rallying Friday morning in response to positive trial data for a prostate cancer imaging agent. What Happened The company announced results ...